drugset / Trial / NCT00644956

A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil

NCT00644956

Phase 4 Completed 56 enrolled Viatris Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study was to determine and compare the minimum time required to achieve penile rigidity greater than or equal to 60% at the base of the penis that is sustained for at least 3 minutes measured by Rigiscan®, following visual sexual stimulation post dose of 100 mg sildenafil citrate and 20 mg tadalafil in men with erectile dysfunction (ED).

Timeline

Start
2003-06
Primary completion
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sildenafil Unknown 100 mg Oral
Comparator Tadalafil Small molecule 20 mg Oral

Indications